# Otsuka Pharmaceutical

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/otsuka-pharmaceutical/

## Facts

| Field | Value |
| --- | --- |
| Country | JP |
| Description | company |
| OpenAlex ID | https://openalex.org/F4320324177 |
| ROR ID | https://ror.org/013k5y296 |
| Works | 4,944 |

## Funder papers

Showing 15 of 21.

- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review](https://scholariq.org/papers/global-incidence-of-iga-nephropathy-by-race-and-ethnicity-a-systematic-review/)
- [The societal economic burden of autosomal dominant polycystic kidney disease in the United States](https://scholariq.org/papers/the-societal-economic-burden-of-autosomal-dominant-polycystic-kidney-disease-in/)
- [Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)](https://scholariq.org/papers/double-blind-randomized-placebo-controlled-trial-evaluating-the-efficacy-and/)
- [Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease](https://scholariq.org/papers/emerging-targeted-strategies-for-the-treatment-of-autosomal-dominant-polycystic/)
- [Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/updated-canadian-expert-consensus-on-assessing-risk-of-disease-progression-and/)
- [OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD](https://scholariq.org/papers/overture-a-worldwide-prospective-observational-study-of-disease-characteristics/)
- [Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries](https://scholariq.org/papers/review-on-epidemiology-disease-burden-and-treatment-patterns-of-iga-nephropathy/)
- [Burden in caregivers of patients with schizophrenia, depression, dementia, and stroke in Japan: comparative analysis of quality of life, work productivity, and qualitative caregiving burden](https://scholariq.org/papers/burden-in-caregivers-of-patients-with-schizophrenia-depression-dementia-and/)
- [Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study](https://scholariq.org/papers/disconnect-in-assessments-of-autosomal-dominant-polycystic-kidney-disease-burden/)
- [Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria](https://scholariq.org/papers/hemolysis-induced-by-sars-cov-2-mrna-vaccination-in-patients-with-paroxysmal/)
- [The incidence and prevalence of immunoglobulin A nephropathy in the United States](https://scholariq.org/papers/the-incidence-and-prevalence-of-immunoglobulin-a-nephropathy-in-the-united/)
- [Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/patient-reported-outcomes-measures-polycystic-kidney-disease-burden-and-outcomes/)
- [Quality of Life in Adults with Atopic Dermatitis in Relation to Disease Severity: Nationwide Data in Japan](https://scholariq.org/papers/quality-of-life-in-adults-with-atopic-dermatitis-in-relation-to-disease-severity/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.